Agios Pharma (AGIO) Misses Q4 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. S
10. COF

Go back to Agios Pharma (AGIO) Misses Q4 EPS by 15c

Agios Reports Fourth Quarter and Full Year 2017 Financial Results

February 14, 2018 7:01 AM EST

All 2017 Key Milestones Achieved, Including First U.S. Product Approval from Agios Discovery Platform and NDA Submission for Second Product Candidate, Ivosidenib, for IDH1m R/R AML

2018 Priorities Focus on Expanding Clinical and Research Programs to Drive Long-Term Value

  2017 Year-End Cash, Cash Equivalents and Marketable Securities was $568M; January Follow-on Offering of $516M Extends Cash Runway Through at Least the End of 2020

CAMBRIDGE, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the... More